• SPX
  • $5,832.92
  • 0.16 %
  • $9.40
  • DJI
  • $42,233.05
  • -0.36 %
  • -$154.52
  • N225
  • $39,277.39
  • 0.96 %
  • $373.71
  • FTSE
  • $8,219.61
  • -0.8 %
  • -$66.01
  • IXIC
  • $18,712.75
  • 0.78 %
  • $145.56
Amgen Inc. (AMGN) Stock Price, News & Analysis

Amgen Inc. (AMGN) Stock Price, News & Analysis

Currency in USD Disclaimer

$316.00

-$1.17

(-0.37%)

Day's range
$314.82
Day's range
$319.21
50-day range
$312.16
Day's range
$339.17
  • Country: US
  • ISIN: US0311621009
52 wk range
$249.7
Day's range
$346.85


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.42
  • Piotroski Score 5.00
  • Grade Overweight
  • Symbol (AMGN)
  • Company Amgen Inc.
  • Price $316.00
  • Changes Percentage (-0.37%)
  • Change -$1.17
  • Day Low $314.82
  • Day High $319.21
  • Year High $346.85

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

  • Last Earnings 10/25/2024
  • Ex-Dividend for 5/16 Dividend 11/18/2024
  • Dividend Payable 12/09/2024
  • Today N/A
  • Next Earnings (Estimated) 10/30/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $303.00
  • High Stock Price Target $380.00
  • Low Stock Price Target $182.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $7.00
  • Trailing P/E Ratio 43.57
  • Forward P/E Ratio 43.57
  • P/E Growth 43.57
  • Net Income $6.72 B

Income Statement

Quarterly

Annual

Latest News of AMGN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.